@article{3085107,
    title = "The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy
on specific immune parameters in patients with colorectal cancer - A
comparative study",
    author = "Tsavaris, NB and Katsoulas, HL and Kosmas, C and Papalambros, E and and Gouveris, P and Papantoniou, N and Rokana, S and Kosmas, N and and Skopeliti, M and Tsitsilonis, OE",
    journal = "DIAGNOSTIC ONCOLOGY",
    year = "2004",
    volume = "67",
    number = "5-6",
    pages = "403-410",
    publisher = "Karger",
    doi = "10.1159/000082925",
    keywords = "colorectal cancer; immune responses; cytokines; monoclonal antibody
17-1A; immunotherapy",
    abstract = "Objectives: We investigated the immune profile of patients with resected
Dukes’ stage C colorectal cancer (CRC), receiving adjuvant therapy with
edrecolomab (Mo17-1A) or first-line 5-fluorouracil (5-FU)-based
chemotherapy. Patients and Methods: Patients received either 5 doses of
Mo17-1A over 13 weeks, or 5-FU/leucovorin, or 5-FU/levamisole over 6 and
12 months, respectively. Peripheral blood was collected postoperatively
and 4 months after therapy initiation. Peripheral blood mononuclear
cells were tested in the autologous mixed lymphocyte reaction (AMLR),
for natural killer (NK) and lymphokine-activated killer (LAK) cell
activity. Serum cytokines were quantified by ELISA. Results: Fifty-two
patients entered the study. Postoperatively, they exhibited decreased
levels of interleukin (IL)-2, interferon-gamma, IL-12,
granulocyte-macrophage colony-stimulating factor and IL-15, low cellular
immune responses ( AMLR, NK- and LAK-cytotoxicity) and increased levels
of IL-1beta, tumor necrosis factor-alpha, IL-6, IL-10 and prostaglandin
E-2. After four months of therapy, patients receiving edrecolomab
demonstrated enhanced AMLR, NK, LAK activity, increased serum levels of
cytokines regulating such responses and reduced levels of acute-phase
cytokines and immune suppressors, compared to patients treated with
conventional chemotherapy. Conclusions: Postoperative adjuvant therapy
with edrecolomab restores the in vivo deficient immune responses of
patients with resected Dukes’ C CRC despite its clinical ineffectiveness
in recent randomized adjuvant trials. These results suggest that further
immunological studies with the combination of edrecolomab and
chemotherapy are required. Copyright (C) 2004 S. Karger AG, Basel."
}